News
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
1 Mar 23
Analyst Color, Biotech, News, Health Care, Price Target, Initiation, Small Cap, Analyst Ratings, Movers, Trading Ideas, General
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
1 Mar 23
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Guggenheim Initiates Coverage On Travere Therapeutics with Buy Rating, Announces Price Target of $37
1 Mar 23
News, Price Target, Initiation, Analyst Ratings
Reported Late Tuesday Feb. 28, Travere Therapeutics Announces Pricing Of $200M Upsized Public Offering Of 8.275M Shares Of Common Stock At A Price Of $21/Share And 1.25M Pre-Funded Warrants
1 Mar 23
News, Offerings
Travere Therapeutics's Return On Capital Employed Overview
28 Feb 23
Earnings
Canaccord Genuity Maintains Buy on Travere Therapeutics, Lowers Price Target to $42
28 Feb 23
News, Price Target, Analyst Ratings
Travere Therapeutics Announces Proposed Public Offering Of $175M Shares Of Common Stock
27 Feb 23
News, Offerings
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $40 Price Target
24 Feb 23
News, Price Target, Reiteration, Analyst Ratings
Travere Therapeutics Q4 EPS $(0.76) Beats $(1.07) Estimate, Sales $55.87M Beat $53.01M Estimate
23 Feb 23
Earnings, News
Earnings Scheduled For February 23, 2023
23 Feb 23
Earnings
Travere Therapeutics's Earnings Outlook
22 Feb 23
Earnings
What 10 Analyst Ratings Have To Say About Travere Therapeutics
22 Feb 23
Analyst Ratings
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $44
22 Feb 23
News, Price Target, Analyst Ratings
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
21 Feb 23
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Tuesday's Intraday Session
21 Feb 23
Movers
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
21 Feb 23
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
21 Feb 23
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $46
21 Feb 23
News, Price Target, Analyst Ratings
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
21 Feb 23
Biotech, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
Wedbush Upgrades Travere Therapeutics to Outperform, Announces $30 Price Target
21 Feb 23
News, Upgrades, Price Target, Analyst Ratings
Press releases
Travere Therapeutics to Present at Upcoming Investor Conferences
28 Mar 23
News, Health Care, Press Releases
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
23 Mar 23
News, Press Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Mar 23
Markets, Press Releases
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
14 Mar 23
News, Health Care, Press Releases
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters' Option to Purchase Additional Shares
3 Mar 23
Press Releases
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
28 Feb 23
Markets, Press Releases
Travere Therapeutics Announces Proposed Public Offering of Common Stock
27 Feb 23
Markets, Press Releases
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 23
Earnings, Press Releases
Ligand's Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
17 Feb 23
Press Releases
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
17 Feb 23
Health Care, Press Releases, General
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
16 Feb 23
News, Press Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Feb 23
Markets, Press Releases
Travere Therapeutics to Present at Upcoming Investor Conferences
8 Feb 23
News, Press Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jan 23
Press Releases
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
News, Press Releases